Jianchao Gao, Xiaoyuan Chen, Chenyan Gao
Center for Drug Evaluation, National Medical Products Administration Beijing China.
Tsinghua Clinical Research Institute (TCRI), School of Medicine Tsinghua University Beijing China.
Health Care Sci. 2024 Aug 6;3(4):264-273. doi: 10.1002/hcs2.108. eCollection 2024 Aug.
The number of medical research publications by Chinese clinical investigators has risen substantially, contributing to 14.63% of the global total in 2019; however, their tangible impact on clinical decision-making remains limited. Various evaluation methods have been developed to measure hospital research competence in China, such as Fudan University's China hospital ranking and Science and Technology Evaluation Metrics (STEM) ranking, which predominantly focuses on factors such as academic reputation, volume of publications and patents, and research resources. However, composite indices may not fully capture the actual clinical value generated by medical research. To address this gap, we introduced the "Clinical Influence and Timeliness Evaluation (CITE)" metric to assess both the clinical importance of a given medical research study and the clinical influence of the hospital where it originated. The methodology used relies on the premise that influential medical research would be referenced in clinical guidelines, which serve as critical resources for clinicians.
The CITE metric was applied for 78,636 medical studies concerning chronic obstructive pulmonary disease (COPD) published between 2000 and 2020 and referenced in both Chinese and international clinical guidelines for COPD. Specific indexes and formulas were derived to quantify the clinical weight of a medical research study (W) and its timeliness (T), enabling a dynamic assessment of the clinical value of each study and the overall contribution of a particular hospital.
In this analysis, we incorporated 499 hospitals in China and quantitatively identified their dynamic clinical influence in COPD from 2000 to 2020. Our findings offer objective and targeted evaluation metrics by focusing on clinical relevance and recognizing the collaborative nature of medical research.
The CITE metric provides an innovative method to gauge the true impact of medical research in China, with potential applications across different medical specialties. CITE can serve as a useful tool for understanding the relationship between research input and practical clinical outcomes, ultimately promoting more clinically relevant research endeavors.
中国临床研究人员发表的医学研究论文数量大幅增加,2019年占全球总数的14.63%;然而,它们对临床决策的实际影响仍然有限。中国已开发出各种评估方法来衡量医院的研究能力,如复旦大学的中国医院排名和科技评估指标(STEM)排名,这些主要侧重于学术声誉、论文和专利数量以及研究资源等因素。然而,综合指标可能无法完全体现医学研究产生的实际临床价值。为了弥补这一差距,我们引入了“临床影响与时效性评估(CITE)”指标,以评估特定医学研究的临床重要性及其发源地医院的临床影响力。所采用的方法基于这样一个前提,即有影响力的医学研究将在临床指南中被引用,而临床指南是临床医生的重要资源。
CITE指标应用于2000年至2020年间发表的78636项关于慢性阻塞性肺疾病(COPD)的医学研究,这些研究在中国和国际COPD临床指南中均有引用。推导了具体指标和公式,以量化医学研究的临床权重(W)及其时效性(T),从而能够动态评估每项研究的临床价值以及特定医院的总体贡献。
在本分析中,我们纳入了中国的499家医院,并定量确定了它们在2000年至202年期间对COPD的动态临床影响。我们的研究结果通过关注临床相关性并认识到医学研究的协作性质,提供了客观且有针对性的评估指标。
CITE指标提供了一种创新方法来衡量中国医学研究的真正影响,在不同医学专业中具有潜在应用。CITE可以作为一个有用的工具,用于理解研究投入与实际临床结果之间的关系,最终促进更具临床相关性的研究工作。